Answers are grounded in this paper and cite their sources.
Review explores technological advances in 3D models highlighting disease modeling and drug discovery implications.
Traditional two-dimensional (2D) neurobiological models do not capture the complex spatial, mechanical, and biochemical microenvironment of the human brain. This limitation has contributed to a high failure rate in translating neuroprotective drugs from the bench to the bedside. Of this review is to explore the technological evolution toward three-dimensional (3D) systems, including neural organoids, scaffold-based hydrogels, and microfluidic Organ-on-Chip (OoC) platforms. This review discusses how these systems facilitate realistic synaptic connectivity and neurovascular unit modeling. By mimicking the native extracellular matrix (ECM) and introducing dynamic fluid flow, these models provide a more accurate representation of human CNS pathophysiology. A specific examination of the role of mechanotransduction and the blood-brain barrier (BBB) in disease progression is provided. Furthermore, the integration of patient-derived induced pluripotent stem cells (iPSCs) for high-fidelity disease modeling and personalized drug screening is highlighted, allowing for the observation of disease phenotypes—such as amyloid-beta (A β ) aggregation and phosphorylated tau—that are often absent in 2D or animal models. 3D neurobiological models represent an evolving approach toward precision medicine, providing platforms that better replicate the physiological complexities of neurodegenerative and neurodevelopmental disorders.
No takes yet. Share an insight, caveat, or question.
Farnam Gholipour Maralan (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: